Evidence map›Paper›PMID 31476572›Full record

ArticleDNA repair2019

Modification of the base excision repair enzyme MBD4 by the small ubiquitin-like molecule SUMO1.

Mara Sannai, Valentina Doneddu, Veda Giri, Steven Seeholzer, Emmanuelle Nicolas, Shu-Chin Yip, Maria Rosaria Bassi, Pietro Mancuso, Salvatore Cortellino, Antonio Cigliano and 7 more

Open access · greenAbstract read
In one paragraph

Article in DNA repair, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. SUMO and the DNA damage response.Biochemical Society transactions · 2024
    Review
  4. Review
  5. Noncatalytic Domains in DNA Glycosylases.International journal of molecular sciences · 2022
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 2 countries.

Mara SannaiCancer Epigenetics and Cancer Biology Programs, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.
Valentina DonedduCancer Epigenetics and Cancer Biology Programs, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA; Department of Biomedical Sciences, University of Sassari, Sassari, 07100, Italy.
Veda GiriCancer Epigenetics and Cancer Biology Programs, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.
Steven SeeholzerProteomics Core, The Children's Hospital of Philadelphia, Philadelphia PA, 19104, USA.
Emmanuelle NicolasCancer Epigenetics and Cancer Biology Programs, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.
Shu-Chin YipCancer Biology Programs, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.
Maria Rosaria BassiCancer Epigenetics and Cancer Biology Programs, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.
Pietro MancusoCancer Epigenetics and Cancer Biology Programs, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.
Salvatore CortellinoCancer Epigenetics and Cancer Biology Programs, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.
Antonio CiglianoCancer Epigenetics and Cancer Biology Programs, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.
Rebecca LurieCancer Epigenetics and Cancer Biology Programs, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.
Hua DingProteomics Core, The Children's Hospital of Philadelphia, Philadelphia PA, 19104, USA.
Jonathan ChernoffCancer Biology Programs, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.
Robert W SobolDepartment of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.
Timothy J YenCancer Biology Programs, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.
Luigi BagellaDepartment of Biomedical Sciences, University of Sassari, Sassari, 07100, Italy; Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, 19122, USA.
Alfonso BellacosaCancer Epigenetics and Cancer Biology Programs, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA. Electronic address: Alfonso.Bellacosa@fccc.edu.
Fox Chase Cancer Center · USChildren's Hospital of Philadelphia · USTemple University · USUniversity of South Alabama · US

Funding

WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Dietmar J Kappes · 1985 to 2026
$138.8M
The MED1 Protein in DNA Damage Response and RepairR01CA078412 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI BELLACOSA, ALFONSO · 2004 to 2014
$3.7M
Novel approaches to enhance tumor cell cytotoxicity of alkylating agentsR01CA148629 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI SOBOL, ROBERT W · 2010 to 2021
$3.4M
NEW HUMAN DNA REPAIR ENDONUCLEASER29CA078412 · NCI · FOX CHASE CANCER CENTER · PI BELLACOSA, ALFONSO · 1998 to 2002
$619k
TDG as a novel target to enhance gemcitabine killing of pancreatic cancer cellsR21CA191956 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI BELLACOSA, ALFONSO, YEN, TIMOTHY · 2015 to 2016
$427k
Quantitative Real-Time DNA Repair Analysis ToolsR43ES025138 · NIEHS · TREVIGEN, INC. · PI GEORGE, JAY, SOBOL, ROBERT W · 2014 to 2014
$202k
NCI NIH HHS P30 CA006927NCI NIH HHS R01 CA078412NCI NIH HHS R01 CA148629NCI NIH HHS R21 CA191956NCI NIH HHS R29 CA078412NIEHS NIH HHS R43 ES025138
6 · The paper itself

Abstract

The base excision repair DNA N-glycosylase MBD4 (also known as MED1), an interactor of the DNA mismatch repair protein MLH1, plays a central role in the maintenance of genomic stability of CpG sites by removing thymine and uracil from G:T and G:U mismatches, respectively. MBD4 is also involved in DNA damage response and transcriptional regulation. The interaction with other proteins is likely critical for understanding MBD4 functions. To identify novel proteins that interact with MBD4, we used tandem affinity purification (TAP) from HEK-293 cells. The MBD4-TAP fusion and its co-associated proteins were purified sequentially on IgG and calmodulin affinity columns; the final eluate was shown to contain MLH1 by western blotting, and MBD4-associated proteins were identified by mass spectrometry. Bands with molecular weight higher than that expected for MBD4 (˜66 kD) yielded peptides corresponding to MBD4 itself and the small ubiquitin-like molecule-1 (SUMO1), suggesting that MBD4 is sumoylated in vivo. MBD4 sumoylation was validated by co-immunoprecipitation in HEK-293 and MCF7 cells, and by an in vitrosumoylation assay. Sequence and mutation analysis identified three main sumoylation sites: MBD4 is sumoylated preferentially on K137, with additional sumoylation at K215 and K377. Patterns of MBD4 sumoylation were altered, in a DNA damage-specific way, by the anti-metabolite 5-fluorouracil, the alkylating agent N-Methyl-N-nitrosourea and the crosslinking agent cisplatin. MCF7 extract expressing sumoylated MBD4 displays higher thymine glycosylase activity than the unmodified species. Of the 67 MBD4 missense mutations reported in The Cancer Genome Atlas, 14 (20.9%) map near sumoylation sites. These results indicate that MBD4 is sumoylated in vivo in a DNA damage-specific manner, and suggest that sumoylation serves to regulate its repair activity and could be compromised in cancer. This study expands the role played by sumoylation in fine-tuning DNA damage response and repair.

Indexed as

DNA RepairAmino Acid SequenceBinding SitesDNA DamageEndodeoxyribonucleasesHEK293 CellsHumansMCF-7 CellsMutationNeoplasmsSUMO-1 ProteinSumoylationEndodeoxyribonucleasesMBD4 protein, humanSUMO-1 ProteinSUMO1 protein, humanDNA damageMBD4/MED1SUMO1Sumoylation

Identifiers

PMID31476572
PMCPMC6785017
OpenAlexW2967254729

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.